Trial Information

Summary: PHI-55 NCI#7427: A Phase I Study of Halichondrin B Analog (E7389) in Combination with Cisplatin in Advanced Solid Tumors

You have been asked to participate in this research study because you have cancer that is no longer controlled with standard therapy or for which no standard therapy exists.  The purpose of this study is to evaluate the safety and feasibility of combining cisplatin with E7389 (E7389 is an investigational or experimental anti-cancer agent that has not yet been approved by the Food and Drug Administration for use) for the treatment of advanced cancer. Another purpose is to evaluate the highest dose of cisplatin and E7389 that can be given without causing unmanageable side effects.  A third purpose is to study the levels of this combination of drugs that remain in the body over time. Researchers will also look at tumor specimens to find out whether the effects of the drug are related to different biological characteristics (diseases that are passed on in families) of the cancer. Your participation in this study is expected to last for at least eight weeks but may be longer if your disease remains the same or is improving and if the side effects are bearable.  After you discontinue treatment, your medical condition will continue to be followed indefinitely.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: October 6, 2008 at 2:41:42 PM